Europe Watches Conflicts of Interest

The European Medicines Agency revised its policy on conflicts of interest in response to concerns regarding its ability to conduct independent evaluations.

By | April 5, 2012

Flickr, Seattle Municipal Archives

FLICKR, SEATTLE MUNICIPAL ARCHIVES

The European Medicines Agency, which oversees evaluation and approval of medical products in the European Union, has strengthened rules aimed at preventing conflicts of interest in its employees, reported InPharm. The new rules aim to reduce ties between board members and the pharmaceutical industry, increase scrutiny of declared conflicts of interest, and institute new procedures when conflicts of interest are not disclosed.

The new policy was spurred by strong criticisms of the EMA by the European Parliament, after the former EMA executive director was suspected of running a consulting group while in office, and left the position in December 2010 to join a pharma consulting firm. Last year, European Parliament expressed severe doubt regarding the EMA’s ability to impartially evaluate human medicines.

EMA’s new director, Guido Rasi, emphasized a new focus on conflicts of interest, telling InPharm, “Since taking up the leadership of the European Medicines Agency in November, one of my main focuses has been on strengthening the ways the Agency deals with conflicts of interests and transparency.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  2. 2017 Top 10 Innovations
    Features 2017 Top 10 Innovations

    From single-cell analysis to whole-genome sequencing, this year’s best new products shine on many levels.

  3. Search for Life on the Red Planet
  4. Two Dozen House Republicans Do an About-Face on Tuition Tax
FreeShip